耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
作者信息
Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y
机构信息
Department of Urology, Gifu University School of Medicine, Japan.
出版信息
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
Abstract
Fifty-five clinical strains of Neisseria gonorrhoeae were examined for mutations in the gyrA and parC genes and for antimicrobial susceptibility profiles. The MICs of quinolones for 31 strains with alterations in GyrA were significantly higher than the MICs for 24 strains without such alterations. Eleven strains with alterations in both GyrA and ParC were significantly more resistant to fluoroquinolones than those with alterations in GyrA alone. The MICs of cephalosporins for these strains were also significantly higher than those for other strains.
摘要
对55株淋病奈瑟菌临床菌株进行了gyrA和parC基因突变及抗菌药物敏感性分析。31株GyrA发生改变的菌株对喹诺酮类药物的最低抑菌浓度（MIC）显著高于24株未发生此类改变的菌株。11株GyrA和ParC均发生改变的菌株对氟喹诺酮类药物的耐药性显著高于仅GyrA发生改变的菌株。这些菌株对头孢菌素类药物的MIC也显著高于其他菌株。
相似文献
1
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
2
Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.天然存在的喹诺酮耐药淋病奈瑟菌菌株对新型喹诺酮类药物的体外敏感性与GyrA和ParC变化的相关性
Antimicrob Agents Chemother. 2001 Mar;45(3):734-8. doi: 10.1128/AAC.45.3.734-738.2001.
3
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.体外筛选携带DNA促旋酶和拓扑异构酶IV改变的耐氟喹诺酮淋病奈瑟菌。
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
4
Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.新型氟喹诺酮类药物DU-6859a对DNA旋转酶GyrA亚基和拓扑异构酶IV的ParC亚基发生基因改变的耐喹诺酮淋病奈瑟菌临床分离株的抗菌活性。
J Antimicrob Chemother. 1997 Feb;39(2):247-9. doi: 10.1093/jac/39.2.247.
5
Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics.在GyrA中含有氨基酸替代、无论是否在ParC中也有替代的淋病奈瑟菌分离株对新型氟喹诺酮类药物和其他抗生素的敏感性。
Antimicrob Agents Chemother. 2000 Jan;44(1):192-5. doi: 10.1128/AAC.44.1.192-195.2000.
6
Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.对具有GyrA和ParC改变的耐喹诺酮淋病奈瑟菌分离株进行血清分型。
J Antimicrob Chemother. 1998 Mar;41(3):418-20. doi: 10.1093/jac/41.3.418.
7
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
8
Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.AM-1155与妥舒沙星和氟罗沙星对携带GyrA和ParC喹诺酮耐药性改变的淋病奈瑟菌临床分离株的体外抗菌活性比较。
Chemotherapy. 1997 Jul-Aug;43(4):239-44. doi: 10.1159/000239573.
9
Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan.日本淋病奈瑟菌分离株中氟喹诺酮耐药性的发展以及涉及GyrA和ParC蛋白的突变
J Urol. 1998 Jun;159(6):2215-9. doi: 10.1016/S0022-5347(01)63308-1.
10
Characterization of Neisseria gonorrhoeae strains with decreased susceptibility to fluoroquinolones isolated in Greece from 1996 to 1999.1996年至1999年在希腊分离出的对氟喹诺酮类药物敏感性降低的淋病奈瑟菌菌株的特征分析
J Clin Microbiol. 2000 Sep;38(9):3489-91. doi: 10.1128/JCM.38.9.3489-3491.2000.
引用本文的文献
1
Target-Mediated Fluoroquinolone Resistance in : Actions of Ciprofloxacin against Gyrase and Topoisomerase IV.氟喹诺酮类药物的靶向耐药性：环丙沙星对拓扑异构酶 II 和拓扑异构酶 IV 的作用。
ACS Infect Dis. 2024 Apr 12;10(4):1351-1360. doi: 10.1021/acsinfecdis.4c00041. Epub 2024 Mar 4.
2
gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy.支原体属生殖器gyrA 基因突变及其对莫西沙星耐药失败的影响：是时候进行下一代耐药指导治疗了。
Clin Infect Dis. 2023 Jun 16;76(12):2187-2195. doi: 10.1093/cid/ciad057.
3
and Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.新型拓扑异构酶抑制剂 TP0480066 对淋病奈瑟菌的作用。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02145-20.
4
PARMAP: A Pan-Genome-Based Computational Framework for Predicting Antimicrobial Resistance.PARMAP：一种基于泛基因组预测抗菌药物耐药性的计算框架。
Front Microbiol. 2020 Oct 22;11:578795. doi: 10.3389/fmicb.2020.578795. eCollection 2020.
5
gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.肯尼亚淋病奈瑟菌氟喹诺酮耐药株中 gyrA 和 parC 突变。
BMC Microbiol. 2019 Apr 8;19(1):76. doi: 10.1186/s12866-019-1439-1.
6
Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant strains isolated in Poland.在波兰分离出的低水平氟喹诺酮耐药菌株中DNA回旋酶基因的变化。
Infect Drug Resist. 2018 Aug 6;11:1047-1053. doi: 10.2147/IDR.S162006. eCollection 2018.
7
Mutations in Neisseria gonorrhoeae grown in sub-lethal concentrations of monocaprin do not confer resistance.在低浓度豆蔻酸中单性生殖奈瑟氏淋病奈瑟菌的突变不会赋予其耐药性。
PLoS One. 2018 Apr 5;13(4):e0195453. doi: 10.1371/journal.pone.0195453. eCollection 2018.
8
Draft Genome Sequence of Neisseria gonorrhoeae Strain NG_869 with Penicillin, Tetracycline and Ciprofloxacin Resistance Determinants Isolated from Malaysia.从马来西亚分离出的具有青霉素、四环素和环丙沙星耐药决定簇的淋病奈瑟菌菌株NG_869的基因组序列草图
Indian J Microbiol. 2016 Jun;56(2):225-7. doi: 10.1007/s12088-016-0568-6. Epub 2016 Feb 8.
9
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.新型DNA回旋酶抑制剂AZD0914的特性：淋病奈瑟菌中耐药潜力低且无交叉耐药性
Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.
10
The use of platensimycin and platencin to fight antibiotic resistance.使用扁枝衣霉素和扁枝衣菌素对抗抗生素耐药性。
Infect Drug Resist. 2013 Sep 18;6:99-114. doi: 10.2147/IDR.S25076.
本文引用的文献
1
2
High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan.日本对氟喹诺酮类药物敏感性降低的淋病奈瑟菌菌株的高流行率。
Genitourin Med. 1994 Apr;70(2):90-3. doi: 10.1136/sti.70.2.90.
3
Detection of the tetM determinant in Neisseria gonorrhoeae.淋病奈瑟菌中tetM决定簇的检测
Sex Transm Dis. 1993 Nov-Dec;20(6):329-33.
4
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构：氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
5
Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents.与盆腔炎相关的淋病奈瑟菌对头孢西丁、头孢曲松、克林霉素、庆大霉素、多西环素、阿奇霉素及其他抗菌药物的敏感性。
Antimicrob Agents Chemother. 1994 Jul;38(7):1688-91. doi: 10.1128/AAC.38.7.1688.
6
Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.淋病奈瑟菌在耐氟喹诺酮类药物的分离株中，gyrA和parC的类似区域会发生突变。
Mol Microbiol. 1994 Oct;14(2):371-80. doi: 10.1111/j.1365-2958.1994.tb01297.x.
7
DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.淋病奈瑟菌喹诺酮耐药临床分离株中的DNA回旋酶突变
Antimicrob Agents Chemother. 1995 Feb;39(2):561-3. doi: 10.1128/AAC.39.2.561.
8
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.大肠杆菌DNA促旋酶gyrA基因中的喹诺酮耐药决定区。
Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2. doi: 10.1128/AAC.34.6.1271.
9
Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae.淋病奈瑟菌中导致低水平萘啶酸耐药的gyrB突变的特征分析。
Antimicrob Agents Chemother. 1991 Apr;35(4):622-6. doi: 10.1128/AAC.35.4.622.
Zotero 插件